A very important achievement has been made by
the research team of Goldyne Savad gene therapy Institute at Hadassah University
Hospital (Jerusalem), as they managed is to prohibit the expansion of
pancreatic cancer to patients.
 |
| Hadassah University Hospital (Jerusalem) |
The success was recorded during the completion of Stage I clinical study using
gene therapy to treat locally advanced pancreatic cancer in patients whose
cancer is inoperable. The results demonstrated that cancer did not proceed to
any of the patients, increasing significantly overall survival. Currently, the Institute will proceed to Stage
II clinical trial.
Goldyne Savad Gene Therapy Institute- founded in 1999- houses the
«National Good Manufacturing Practice» (GMP), the center for the production
of biopharmaceuticals and the clinical site where new drugs can be
tested as part of research for stages
I and II.
The
Institute is currently composed of 13 research groups with 90
researchers; produces work that help doctors treat
patients suffering from various
diseases such as heart failure,
cancer and macular degeneration. These treatments include the use of viral and non-viral gene delivery systems, as well as stem
cell therapy.
Furthermore,
a protein therapy has been developed
for acute myocardial infarction, proved to have significantly reduced heart failure.
Meanwhile, a new drug combination is being studied to fight neuroblastoma,
the most common extracranial solid cancer that affects
children (which represents approximately 15% of deaths related to cancer in childhood).
Translated & Edited by Christiana Vellianiti
Source:briefingnews.gr
No comments:
Post a Comment